公司資料
Adagene 股價、新聞與催化劑
- 股票代碼:
- ADAG
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- China and listed in the U
股票表現
3.83 USD (+3.51%)
收盤價
最後更新: 2026年8月17日
224M USD
市值
股價為何變動
As of Aug 17, 2026, ADAG closed up 3.51% at $3.83. No new same-company headline was identified in the current news window.
公司概覽
業務概覽
Adagene is a biotechnology company focused on next-generation antibody engineering and cancer immunotherapy. Its story is built around precision antibody design and the effort to create differentiated oncology medicines.
所在地與產業分類
Adagene is headquartered in China and listed in the U.S. market. It sits in oncology biotechnology with a platform-engineering identity.
商業模式特徵
The company depends on translational validation, clinical data, and the ability to turn antibody engineering into clinical value. Investors watch proof-of-concept, partnerships, and capital runway.
生技產業定位
Adagene occupies a specialized antibody-engineering niche within biotech. It is catalyst-sensitive because the platform still needs to prove broad therapeutic differentiation.
未來催化劑
- Adagene’s catalysts are its immune-modulating antibody platform and any clinical or partnership update that shows the technology can still differentiate. The company still needs stronger human proof.
近期新聞
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。